9705370-6

RTMP COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		(11) International Publication Number:
C07D 401/12, A61K 31/495	A1	WO 96/40681
		(43) International Publication Date: 19 December 1996 (19.12.96)

(21) International Application Number: PCT/GB96/01295

(22) International Filing Date: 3 June 1996 (03.06.96)

(30) Priority Data:

9511507.7	7 June 1995 (07.06.95)	GB
9519666.3	27 September 1995 (27.09.95)	GB

(71) Applicant: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors: BRADBURY, Robert, Hugh; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). BUTLIN, Roger, John; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). JAMES, Roger; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: BILL, Kevin; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderly Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS

(57) Abstract

The invention concerns pharmaceutically useful compounds of formula (I), in which A^1, A^2, A^3, A^4, B^1, m, Ar, W, X, Y, Z and R^1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.